Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an target dose be established? A ten-year follow-up study.

Context: Intrathecal baclofen (ITB) therapy is administered for severe, persistent spasticity that cannot be addressed by oral medication or other treatments.

Objective: We aimed to evaluate the target dose of ITB for severe, persistent spasticity based on disease etiology.

Methods: Data at baseline (discharge), 1, and 10 years from 102 patients who received ITB therapy between 1985 and 2011 were retrospectively collected.